Drugs / allogeneic NK cells
allogeneic NK cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07225439 | Sep 2026 → Dec 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +2 | Paolo Caimi, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT00877110 | Apr 2009 → Jan 2019 | bone marrow disorder, neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04162158 | Mar 2019 → Oct 2022 | hepatocellular carcinoma | Beijing 302 Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 15
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Oncopeptides AB | Results Research by top universities together with Oncopeptides on NK cell engagers to be presented at ASH oncopeptides.com ↗
In preclinical models, the combination demonstrated synergistic anti-myeloma activity, efficient tumor cell lysis, and reduced cytokine release compared to existing T-cell-based strategies, supporting the potential of this new modality as a novel immunotherapeutic approach for relapsed or refractory multiple myeloma. |
| 2024-06-14 | Wugen, Inc. | Results Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress wugen.com ↗
WU-NK-101 is an Off-The-Shelf Memory NK Cell with a Time-Resilient, Anti-Tumor Phenotype that can be Detected in R/R AML Patient PBMC After Infusion |
| 2024-05-15 | Senti Biosciences | Results Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits sentibio.com ↗
Selective killing of tumor cells is validated in vivo in a mixed target cell model |
| 2024-04-08 | Celularity Incorporated | Results Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells celularity.com ↗
The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024. |
| 2023-06-10 | Nkarta, Inc. | Results Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma nkartatx.com ↗
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation study |
| 2023-04-27 | Celularity Incorporated | Results Celularity Announces Clinical Data on Human Placental-derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate CYNK-001 in Adult Patients With Relapsed Refractory And Measurable Residual Disease-positive Acute Myeloid Leukemia celularity.com ↗
In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose, two of four patients achieved an objective response at Day 28 |
| 2022-12-11 | Wugen, Inc. | Results Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting wugen.com ↗
These data functionally characterizing the anti-tumor properties of WU-NK-101 are highly encouraging and support the potential for WU-NK-101 as a treatment for relapsed/refractory (r/r) AML. |
| 2022-09-26 | Celularity Incorporated | Results Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro celularity.com ↗
The study demonstrated how IAV sensitizes infected cells for targeting by CYNK-001 via multiple stress ligand and NK receptor activating pathways. |
| 2022-04-25 | Nkarta, Inc. | Results Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs nkartatx.com ↗
3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate) |
| 2022-04-08 | Editas Medicine, Inc. | Results Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting editasmedicine.com ↗
Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and extended survival supporting continued development as a novel therapeutic approach for solid tumors |
| 2021-12-13 | Celularity Incorporated | Results Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition celularity.com ↗ |
| 2021-12-12 | Editas Medicine, Inc. | Results Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting editasmedicine.com ↗
iNKs with double knock-in of CD16 and mbIL-15 in combination with monoclonal antibody significantly reduce tumor burden |
| 2021-11-15 | Celularity Incorporated | Results Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting celularity.com ↗
The results demonstrate the synergistic effect of combining CYNK-101 with Cetuximab to drive antibody dependent cellular cytotoxicity activity against EGFR + tumors. |
| 2021-11-12 | Editas Medicine, Inc. | Results Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting editasmedicine.com ↗
The modifications resulted in improved serial tumor killing and dramatically increased NK cell persistence. |
| 2020-03-17 | AvenCell Europe GmbH | Results GEMoaB Announces Publication of Pre-Clinical Proof-of-Concept Data on UniCAR-modified off-the-shelf Natural Killer Cells in “Nature Scientific Reports” avencell.com ↗
GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced that “Nature Scientific Reports” has published pre-clinical proof-of-concept data on UniCAR-modified off-the-shelf Natural Killer (NK) cells targeting GD2-expressing tumors (Mitwasi et al. 2020, 10:2141). |
All press releases naming this drug 23 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04162158 ↗ |
| Known as | natural killer (NK) cells | “natural killer (NK) cells” NCT00877110 ↗ |
| Known as | NK cells | “natural killer (NK) cells” NCT00877110 ↗ |
| Modality | Cell therapy | “combination of adoptive NK cell therapy with RT significantly improved therapeutic efficacy” PMID 37981041 ↗ Nov 2023 |
| Route | Intravenous | “Allogeneic NK cells are given intravenously (IV) weekly for 3 weeks on Days 0, 7, 14.” NCT07225439 ↗ |